GP262

GP262 is a PI3K/mTOR PROTAC degrader targeting PI3Kγ, PI3K, and mTOR, with DC50 values of 42.23 nM and 45.4 nM in MDA-MB-231 cells. It induces degradation of p110α and p110γ with DC50 values of 42.23 nM, 227.4 nM, and 45.4 nM, respectively. GP262 exhibits substantial antiproliferative activity and induces apoptosis (apoptosis) in vitro. It effectively modulates the PI3K/AKT/mTOR signaling pathway and degrades target proteins via the ubiquitin-proteasome system. In vivo, GP262 shows tumor growth inhibition and good biosafety. This compound is useful for research in leukemia and triple-negative breast cancer (TNBC) .